Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 513601 - Provider product page
- Provider
- BioLegend
- Proper citation
- BioLegend Cat#513601, RRID:AB_2248930
- Product name
- Purified anti-human IL-32
- Antibody type
- Monoclonal
- Antigen
- Recombinant human IL-32α
- Description
- Interleukin 32 (IL-32),previously known as a transcript (NK4), is produced by mitogen-activated lymphocytes, by IFNγ-activated epithelial cells or by IL-12 and IL-18-activated NK cells.Its expression is increased following activation of T-cells by mitogens or the activation of NK cells by IL-2.IL-32 activates NF-κ-B and p38 MAPK cytokine signal pathways. It has been suggested that IL-32 may play a role in autoimmune and inflammatory diseases such as rheumatoid arthritis.IL-32 is unusual in that it does not share sequence homology with known cytokine families and is highly expressed in immune tissues. IL-32 exists in at least four differentially spliced isoforms (α, β, γ and δ)with predicted molecular weight: ~26 kD.IL-32α is the shortest and most abundant of four potential splice variants of the pro-inflammatory cytokine IL-32.Potential modifications include myristoylation and N-glycosylation. Transfected IL-32 alpha was more likely to be cell-associated as compared to IL-32β, suggesting an intracellular function.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 50 µg
- Concentration
- 0.5 mg/ml
- Storage
- The antibody solution should be stored undiluted at 4°C.
Submitted references Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease.
Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
Greene CM, Low TB, O'Neill SJ, McElvaney NG
American journal of respiratory and critical care medicine 2010 Jan 1;181(1):31-5
American journal of respiratory and critical care medicine 2010 Jan 1;181(1):31-5
Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
Kulkarni O, Eulberg D, Selve N, Zöllner S, Allam R, Pawar RD, Pfeiffer S, Segerer S, Klussmann S, Anders HJ
The Journal of pharmacology and experimental therapeutics 2009 Feb;328(2):371-7
The Journal of pharmacology and experimental therapeutics 2009 Feb;328(2):371-7
No comments: Submit comment
No validations: Submit validation data